Opus Genetics (NASDAQ:IRD) Issues Earnings Results

Opus Genetics (NASDAQ:IRD) posted its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.59), Zacks reports. The company had revenue of $2.16 million for the quarter, compared to analyst estimates of $2.93 million. Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 709.20%.

Opus Genetics Stock Performance

Opus Genetics stock traded down $0.08 during midday trading on Thursday, reaching $4.95. 580,869 shares of the company were exchanged, compared to its average volume of 911,391. The company has a market capitalization of $353.15 million, a price-to-earnings ratio of -3.74 and a beta of 0.62. The firm’s 50-day simple moving average is $4.97 and its 200-day simple moving average is $3.31. Opus Genetics has a 1 year low of $0.90 and a 1 year high of $5.81.

Insider Activity

In other Opus Genetics news, CFO Robert E. Gagnon sold 7,842 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $5.18, for a total transaction of $40,621.56. Following the sale, the chief financial officer directly owned 592,158 shares of the company’s stock, valued at $3,067,378.44. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Benjamin R. Yerxa sold 7,470 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.24, for a total transaction of $39,142.80. Following the completion of the transaction, the president directly owned 711,535 shares of the company’s stock, valued at approximately $3,728,443.40. This represents a 1.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 73,395 shares of company stock valued at $382,278 in the last 90 days. Company insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp acquired a new stake in Opus Genetics in the 4th quarter worth about $177,000. Marshall Wace LLP purchased a new stake in Opus Genetics in the 4th quarter valued at about $317,000. State Street Corp lifted its holdings in shares of Opus Genetics by 18.8% during the 4th quarter. State Street Corp now owns 173,253 shares of the company’s stock worth $348,000 after acquiring an additional 27,380 shares during the period. Citadel Advisors LLC lifted its holdings in shares of Opus Genetics by 496.9% during the 3rd quarter. Citadel Advisors LLC now owns 113,416 shares of the company’s stock worth $187,000 after acquiring an additional 94,416 shares during the period. Finally, Creative Planning purchased a new position in shares of Opus Genetics during the 3rd quarter worth about $212,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, giving management a venue to highlight its clinical-stage gene therapy pipeline and potentially attract investor attention. Article Title
• Positive Sentiment: Citizens JMP kept a “market outperform” rating on Opus Genetics even as it trimmed its price target to $11 from $12, signaling continued upside expectations. Article Title
• Positive Sentiment: Earlier analyst commentary from the Globe and Mail flagged Opus Genetics among bullish healthcare names, reinforcing that some analysts remain constructive on the shares. Article Title
• Neutral Sentiment: Analysts have issued conflicting views on Opus Genetics, with some reports highlighting bullish sentiment while others point to caution, suggesting investor expectations are still unsettled. Article Title
• Neutral Sentiment: The company is expected to report earnings soon, which could create a catalyst for volatility as investors wait for updated financial results. Article Title
• Negative Sentiment: Zacks Research downgraded Opus Genetics from “hold” to “strong sell,” adding pressure on sentiment around the stock. Article Title
• Negative Sentiment: Lifesci Capital lowered its FY2026, Q2 2026, and Q3 2026 earnings estimates, indicating analysts now expect deeper losses than previously forecast. Article Title

Analyst Ratings Changes

IRD has been the subject of several research analyst reports. Citigroup initiated coverage on Opus Genetics in a research note on Tuesday, April 28th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a report on Tuesday, April 21st. Craig Hallum set a $9.00 price target on Opus Genetics and gave the company a “buy” rating in a research report on Wednesday, March 11th. Zacks Research downgraded shares of Opus Genetics from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, Oppenheimer began coverage on shares of Opus Genetics in a research report on Monday, March 16th. They set an “outperform” rating and a $10.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Opus Genetics presently has an average rating of “Moderate Buy” and an average price target of $10.20.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.